Mantle cell lymphoma - Does primary intensive immunochemotherapy improve overall survival for younger patients?

Leukemia and Lymphoma

Volumn 50, Issue 8, 2009, Pages 1249-1256

  Geisler, Christian ^a   Kolstad, Arne ^b   Laurell, Anna ^c   Räty, Riikka ^d   For Nordic Lymphoma Group, ^a   Mantle Cell Lymphoma Subcommittee, ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

autologous stem cell transplantation; immunochemotherapy; Mantle cell lymphoma

Indexed keywords

ALPHA INTERFERON; BENDAMUSTINE; BORTEZOMIB; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; KI 67 ANTIGEN; LENALIDOMIDE; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE; YTTRIUM 90; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; IMMUNOCHEMOTHERAPY; LEUKOPENIA; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; AGE; AGED; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; PROTO ONCOGENE; STATISTICS; SURVIVAL;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTE SUBSETS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GENES, BCL-1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; VINCRISTINE;

EID: 77249104905     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903040030     Document Type: Review

References (50)

1. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494. (Pubitemid 26162353)
2. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-1213.
3. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
4. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinocopathological study from the European MCL Network. Br J Haematol 2005;131:29-38. (Pubitemid 43899705)
5. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome in advanced mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy. Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008;111:2385-2387. (Pubitemid 351451450)
6. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-4321. (Pubitemid 41775942)
7. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapies. Nat Med 2007;7:750-762. (Pubitemid 47463673)
8. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International lymphoma Study group classification of non-Hodgkin's lymphoma. Blood 1997;87:3909-3918.
9. Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998;16:1922-1930.
10. Andersen NS, Jensen MK, de Nully Brown P, et al. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401-408. (Pubitemid 34121968)
11. Zhou Y, Wang H, Wenjing F, et al. Incidence trends of mantle cell lymphoma in the Unites States between 1992 and 1998. Cancer 2008;113:791-798.
12. Salar A, Juanpere N, Bellosillo B, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006;30:1274-1280. (Pubitemid 44454707)
13. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 2008;111:558-565.
14. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-197. (Pubitemid 37443390)
15. Hartmann E, Fernández V, Moreno V, et al. Five gene model to predict prognosis in mantle cell lymphoma. J Clin Oncol 2008;26:4966-4972.
16. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose metothrexate/cytarabine followed by stem cell transplantation: an active regimen for mantle cell lymphoma. J Clin Oncol 1998;16:3803-3809. (Pubitemid 29001533)
17. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs event-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
18. Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003;71:73-80. (Pubitemid 36951639)
19. Lefrere F, Delmer A, Levy V, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002;16:587-593. (Pubitemid 34449738)
20. Magni M, di Nicola M, Carlo-Stella C, et al. High-dose sequential chemotherapy and in vivo purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R. HDS regimen. Bone Marrow Transplant 2008;96:864-869.
21. Geisler C, Kolstad A, Laurell A, et al. Long-term progressionfree survival of mantle cell lymphoma after intensive front-line immunochemotherapu with in-vivo purged stem cell rescue: a non-andomized phase-2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
22. van't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009;144:524-530.
23. Tam CS, Bassett R, Ledesma C, et al. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144-4152.
24. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
25. Epner EM, Unger J, Miller T, et al. A Multi Center Trial of hyper CVAD +Rituxan in patients with newly diagnosed mantle cell lymphoma [abstract]. Blood (Suppl) 2007;110:121a (Abstract 387).
26. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989;5:365-380. (Pubitemid 19213752)
27. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000;64:190-196. (Pubitemid 30409035)
28. Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567-575. (Pubitemid 28112997)
29. Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995;85:1075-1082.
30. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992. (Pubitemid 46211378)
31. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
32. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of event-free survival. J Clin Oncol 2002;20:1288-1294. (Pubitemid 34177435)
33. Dreyling M, Hoster E, Hermine O, et al. European MCL Network: an update on current first line trials. Blood (Suppl) 2007;110:121a (Abstract 388).
34. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclphosphamise, mitoxantrone (FCM) significantly increases the response rate and prolongs survival compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lumphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071. (Pubitemid 39517009)
35. Eve HE, Seymour JF, Rule SA. Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/7 rituximab. Leuk Lymphoma 2009;50:211-215.
36. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-3389.
37. Rummel M, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in firstline treatment of patients with follicular, indolent and mantle cell lymphomas. Results of a trandized phase-III study of the Study Group Indolent Lymphomas (StiL). Blood 2008;112:900 (Abstract 2596).
38. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-714. (Pubitemid 47078732)
39. Romaguera JE, Fayad L, Rodriguez MA, et al. Rituximab (R) plus hyper-CVAD alternating with R-Methotrexate/Cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma. Blood 2008;112:309 (Abstract 833).
40. Jacquy C, Lambert F, Soree A, et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging? Bone Marrow Transplant 1999;23:681-686. (Pubitemid 29176531)
41. Dreger P, Rieger M, Seyfarth B, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007;92:42-49. (Pubitemid 46237555)
42. Milpied N, Gaillard F, Moreau P, et al. High-dose therapy with stem-cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998;22:645-650. (Pubitemid 28486362)
43. 90Y)-ibritumomab-tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2007;40:1007-1017. (Pubitemid 350147685)
44. Park SI, Press OW. Radioimmunotherapy for treatment of lymphomas and other hematologic malignancies. Curr Opin Hematol 2007;14:632-638. (Pubitemid 47494079)
45. Ghielmini M, Schmitz S F H, Cogliatti S, et al. Effect of singleagent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma. A study of the Swiss group for clinical cancer research (SAKK). J Clin Oncol 2005;23:705-711. (Pubitemid 46224169)
46. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008. (Pubitemid 44920177)
47. Ladetto M, Magni M, Pagliano G, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006;12:1270-1276. (Pubitemid 44858257)
48. Andersen NS, Pedersen LB, Laurell A, et al. Successful preemptive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Blood 2007;110:386a (Abstract 1281).
49. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003;120:793-800. (Pubitemid 36315101)
50. Maris MB, Sandmaier B, Storer B, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-3542. (Pubitemid 39564424)